

## Presentation Title 报告标题:

Accelerating Lead Optimization Chemistry with In-depth Structure-Druggability (Drug-like Property) Relationship (SDR) Studies

基于“结构-类药性”关联研究的先导化合物优化

## Speaker 报告人:


Yaoqiu Zhu, Ph.D., Chief Research Investigator, MetabQuest Research and Consulting

朱耀球 博士 北京和济美代医药技术研究有限公司(美代研究) 首席研究员

## Abstract 报告摘要:

ADME-Tox study has become an essential part of drug discovery research, aiming to build the necessary druggabilities ("drug-like" properties) into drug candidates with higher success probabilities in preclinical and clinical studies.

In-depth structure-druggability (drug-like properties) relationship (SDR) studies can accelerate lead optimization chemistry programs in many ways: 1. Dial out soft spot quickly for lead modification; 2. Detect reactive/toxic metabolite and provide chemical strategy to minimize tox risk of the lead series; 3. Provide me-better approaches for follow-on program; 4. Identify animal species for tox studies of lead series; 5. Identify the correct in vitro system that predicts in vivo behaviors of lead series; 6. Track druggability behind structural progression of lead compound; 7. Address PK-PD discrepancy in animal studies; 8. Design and evaluate prodrug approaches for lead series; etc..



This seminar is based on case studies from different lead optimization programs at different stages demonstrating the assisting role of SDR studies and how to do in-depth SDR studies to accelerate lead optimization chemistry programs.

## Invited Seminars 报告经历:

2010.09 School of Pharmaceutical Sciences, Peking University, Beijing, China 北京 北京大学药学院

2010.09 Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China 上海 中科院上海药物所

2010.08 Pharmaron, Beijing, China 北京 康龙化成

2010.07 Tasly Pharmaceuticals, Tianjin, China 天津 天士力制药

2009.11 Beijing Hanmi Pharm, Beijing, China 北京 韩美药品

2009.10 7<sup>th</sup> Annual Congress of International Drug Discovery Science and Technology, Shanghai, China

2009.10 Chinese Medicinal Chemistry Symposium 2009, Wuhan, China

2009.09 Department of Chemistry, Northwestern University, Evanston, IL, USA

2009.07 Bridge Laboratories, Beijing, China 北京 维通博际

2009.07 BioDuro, Beijing, China 北京 保诺科技

2009.05 Hutchison MediPharma, Shanghai, China 上海 和记黄埔医药

2009.05 Shanghai ChemPartner, Shanghai, China 上海 睿智化学

2009.03 MicuRx Pharmaceuticals, Shanghai, China 上海 盟科医药

2009.02 Shanghai Heng Rui Pharmaceuticals, Shanghai, China 上海 恒瑞医药

2009.02 Egret Pharmaceutical, Shanghai, China 上海 白鹭医药

2008.12 Midwest BioResearch, Skokie, IL, USA

2008.12 Drug Metabolism Department, Takeda Global Research Center, Lake Forest, IL, USA

2008.11 Hit-to-lead Department, Abbott Laboratories, IL, USA

2008.11 Preclinical Drug Metabolism Department, Abbott, IL, USA

2008.11 Neuroscience Research Division, Abbott, IL, USA

2008.08 Medicinal Chemistry Department, Abbott Bioresearch Center, Worcester, MA, USA